CME Post-Test

This activity has been developed as part of the E-Learning Series and is posted on cancernetwork.com. It will be used to help physicians with their (re)certification or as a clinical review.

About the Activity

This activity is based on a brief article developed as part of the E-Board Review and posted on the Web. The series is geared to oncologists and addresses new treatments of cancer or modifications thereof.

This activity has been developed and approved under the direction of Beam Institute.

Activity Learning Objectives

After completing this review, the clinician should be able to:

(1) Describe the latest recommendations for screening of women at high risk for breast cancer.

(2) Discuss adjuvant treatment options for invasive breast cancer.(3) Define the role of aromatase inhibitors and endocrine therapy in the prevention of disease recurrence.

(4) Explain the benefits and limitations of the tests available for determining risk of disease recurrence.

(5) Evaluate use of anthracyclines in the treatment of breast cancer patients.

Target Audience

This activity targets physicians in the fields of oncology and hematology.

Accreditation

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Beam Institute and The Oncology Group. Beam Institute is accredited by the ACCME to provide continuing medical education for physicians.

Continuing Education Credit

AMA PRA Category 1 Credit™

The Beam Institute designates this educational activity for a maximum of 3 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Compliance Statement

This activity is an independent educational activity under the direction of Beam Institute. The activity was planned and implemented in accordance with the Essential Areas and policies of the ACCME, the Ethical Opinions/Guidelines of the AMA, the FDA, the OIG, and the PhRMA Code on Interactions with Healthcare Professionals, thus assuring the highest degree of independence, fair balance, scientific rigor, and objectivity.

However, Beam Institute, the Grantor, and CMPMedica shall in no way be liable for the currency of information or for any errors, omissions, or inaccuracies in the activity. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Activity participants are encouraged to refer to primary references or full prescribing information resources. The opinions and recommendations presented herein are those of the author(s) and do not necessarily reflect the views of the provider or producer.

Financial Disclosures

Dr. Ellis has received grant and research support from Novartis and Genentech; he has acted as a consultant for Novartis, AstraZeneca, Johnson and Johnson, and Genentech. Dr. Sorscher has served on speaker's bureaus for Lilly, Genentech, Sanofi-Aventis, Pfizer, and Astra Zeneca. Dr. Ma has no financial information to disclose.

Copyright

Copyright owned by Beam Institute, a division of CME LLC. Copyright 2008, CME LLC. All rights reserved.

Contact Information

We would like to hear your comments regarding this or other activities provided by Beam Institute. In addition, suggestions for future activities are welcome.Contact us at:

@page_break@